Abbott Gets Sub-license to Develop Companion Dx for Pfizer Drug | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Following a patent licensing deal with Cell Signaling Technology, Pfizer will grant a sub-license to Abbott to develop a companion diagnostic test for selecting patients to be treated with Pfizer's crizotinib, an investigational anaplastic lymphoma kinase inhibitor.

Abbott will develop a fluorescence in situ hybridization-based test, under the terms of the sub-license.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.